VEGF与鼻咽癌的研究现况及其临床意义

鼻咽癌是我国南方常见的恶性肿瘤之一,5年生存率持续在50%~60%之间,预后较差。血管内皮生长因子属于血小板源生长因子家族,是目前所知唯一特异作用于血管内皮细胞的因子。它非特异性的低表达于人类大部分组织中,但是在大多数肿瘤组织中异常高表达。VEGF与肿瘤的发生、发展、治疗、预后密切相关,是一个具有潜在价值的肿瘤标志物,有望成为肿瘤靶向治疗的理想新靶点。研究发现,VEGF在鼻咽癌组织中同样存在高表达现象,细胞水平利用VEGF基因沉默技术可以抑制鼻咽癌细胞的增殖,因此以VEGF为靶点的治疗方法可能为临床鼻咽癌治疗开辟新途径。本文就VEGF与鼻咽癌的研究现状作一综述。

The Research Status and the Clinical Significance between VEGF and Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma is one of the common malignant tumor in southern China, that 5-year survival rate is in the range of 50%- 60% and the prognosis is poor. Vascular endothelial growth factor （ VEGF ） belongs to the family of platelet-derived growth factors and so far as the only known specific factor acts to vascular endothelial cells. It expresses lower in most tissues of the human with nonspecific manner and higher abnormally in most tumor tissues. The fact that it is related closely to tumor＇s occurrence, development, treatment and prognosis suggests that VEGF is a potentially valuable tumor marker and also expected to become an ideal new target for targeted cancer therapy. Some studies found that the phenomenon of high expression of VEGF is also occurs in nasopharyngeal carcinoma and gene silence with VEGF siRNA can inhibit the proliferation of nasopharyngeal carcinoma cell lines. Hence, the treatment using VEGF as the target may open new avenues for the clinical treatment of nasopharyngeal carcinoma. In this paper, it is reviewed about the research status of VEGF and nasopharyngeal carcinoma.